生物学杂志

• 综述与专论 • 上一篇    下一篇

不同哮喘表型的靶向治疗研究进展

  

  1. 暨南大学 第二临床医学院 深圳市人民医院 呼吸内科, 深圳 518020
  • 出版日期:2018-04-18 发布日期:2018-04-18
  • 通讯作者: 史菲,硕士生导师,主要研究LIGHT-HVEM/LTβR通路对哮喘CD4+T细胞-气道平滑肌细胞交叉串扰的调控作用及机制,E-mail:shifei2003@126.com
  • 作者简介:乐迎,硕士,主要从事哮喘方面研究,E-mail:320793524@qq.com
  • 基金资助:
    广东省科技计划项目(2016A020215025);广东省医学科研基金(A2016375) 

Progress in targeted therapy of different asthma phenotypes

  1. Department of Respiratory Medicine, Shenzhen People′s Hospital, Jinan University Second Clinical College, Shenzhen 518020, China
  • Online:2018-04-18 Published:2018-04-18

摘要: 哮喘是一种复杂的异质性疾病,存在多种特征各异的临床表型,典型临床表现为反复发作性咳嗽、胸闷、喘息、气促,多于夜间出现,多可自行缓解或使用药物(如短效β受体激动剂沙丁胺醇)后可缓解,其具有反复发作,不断进展的特点,已成为严重的公共卫生问题。其中吸入糖皮质激素( inhaled corticosteroids,ICS)治疗是目前推荐长期控制哮喘病情最有效的治疗,但部分患者即使在使用大剂量激素治疗,甚至联合长效β2 受体激动剂或者白三烯调节剂时仍难以控制病情,这是由于哮喘疾病的异质性导致众多哮喘患者对常规抗哮喘治疗反应不一的重要原因。因此,针对不同哮喘表型开展特异性靶向治疗是今后哮喘研究的重要方向。就几种常见哮喘表型的靶向治疗研究展开综述。

关键词: 哮喘, 表型, 靶向治疗

Abstract: Asthma is a complex and heterogeneous disease with many different clinical phenotypes. Typical clinical manifestations are recurrent cough, chest tightness, wheezing, shortness of breath, more than nighttime, more self-remission or use of drugs(Such as short-acting beta-agonist salbutamol) can be relieved, which has the characteristics of recurrent, and continuous progress has become a serious public health problem. Among them, inhaled corticosteroids(ICS) are the most effective treatments recommended for the long-term control of asthma, but even with high-dose hormone therapy, combinaed with long-acting β2 receptor agonists or leukotriene modulators,the disease is still difficult to control some to patients, and the heterogeneity of asthma caused many asthma patients respond to conventional anti-asthma treatment is an important reason. Therefore, specific targeting therapy for different asthma phenotypes is an important direction for asthma research in the future. This article reviews several common targeted therapies for asthma phenotypes.

Key words: asthma, phenotype, targeted therapy